Investment Rating - The report maintains a "Positive" outlook for the pharmaceutical and biotechnology industry [5] Core Viewpoints - Short-term fluctuations do not change the long-term growth trajectory of the innovative drug sector. Despite recent market volatility, the underlying logic for medium to long-term growth remains intact, driven by globalization, technological breakthroughs, and industry upgrades [8][12] - The focus has shifted from "can we go global" to "what progress has been made after going global," emphasizing the importance of overseas clinical deployment and milestone achievements for innovative drugs [13][14] - Breakthroughs in frontier technologies, particularly in small nucleic acids and CAR-T therapies, position Chinese companies to become core global assets [18][20] - The commercialization of innovative drugs is expected to lead to a profitability inflection point, with key companies entering a positive cycle of product volume growth and reinvestment in R&D [22] Summary by Sections 1. Short-term Fluctuations, Long-term Growth - The innovative drug sector has experienced significant volatility due to concentrated expectations and emotions, but the long-term growth trend remains unchanged [8][12] - The valuation of leading companies has reached reasonable levels, suggesting potential investment opportunities as market sentiment stabilizes [12] 1.1 Focus on Globalization Progress - The emphasis has shifted to the progress of products in overseas clinical trials, with a focus on key data readouts and milestone achievements [13][14] - Domestic bispecific antibodies are accelerating their global clinical trials, becoming core trading assets in the context of expiring patents for PD-(L)1 products [13] 1.2 Breakthroughs in Frontier Technologies - Chinese companies are leading in small nucleic acids and CAR-T therapies, with significant advancements in delivery technologies expanding treatment options beyond rare diseases [18] - In vivo CAR-T therapies have shown preliminary clinical effectiveness, with a growing number of transactions indicating a shift towards mainstream adoption [20] 1.3 Commercialization Driving Profitability - Leading innovative drug companies are entering a cycle of product volume growth that supports R&D reinvestment, with expectations for exceeding market performance in 2023 [22] - The upcoming earnings period in March-April 2026 is seen as a critical validation point for the sector [22] 2. Global New Drugs: Highlights in Autoimmunity and Oncology - The report highlights the approval of the world's first PD-L1/TGF-β bispecific antibody, showcasing the R&D capabilities of domestic companies [26][27] - The successful launch of innovative drugs in critical therapeutic areas reflects the growing strength of domestic pharmaceutical companies in addressing unmet medical needs [26][27]

Group 1 - CICC maintains an "outperform" rating for BeiGene, forecasting $3.9 billion in sales for Zebrutinib in 2025, a 49% year-on-year increase, and $740 million for Tislelizumab, a 19% increase [1] - Multiple significant catalysts are expected in 2026, including U.S. approval for Sotigalimab in R/R MCL, potential accelerated approval for BTK CDAC, and the initiation of Phase III clinical trials for CDK4 [1] Group 2 - CITIC Securities maintains a "buy" rating for Dongfang Zhenxuan, reporting a 5.7% year-on-year revenue increase for FY26H1 and a return to profitability with a net profit of 239 million yuan [2][6] - The self-operated product GMV share increased to 52.8%, with 801 SKUs and the app contributing 18.5% of total GMV [2] Group 3 - CITIC Securities maintains a "buy" rating for Trip.com, reporting a 20.8% year-on-year revenue increase for Q4 2025, slightly exceeding expectations [3] - The international OTA platform saw a 60% increase in bookings for the year, serving 20 million inbound tourists and connecting over 150,000 hotels [3] Group 4 - CITIC Securities maintains a "buy" rating for Samsonite, planning a dual primary listing in the U.S. in the first half of 2026, with IATA predicting a 4.9% increase in global air passenger traffic in 2026 [4] - Current Hong Kong stock valuation is at 11x PE, significantly lower than the comparable U.S. companies at 17x and its historical average of 21x, with the dual listing expected to improve liquidity and catalyze valuation recovery [4] Group 5 - CITIC Securities maintains a "buy" rating for Insilico Medicine, highlighting partnerships with Exelixis and Menarini for high-value pipeline collaborations [5] - The core pipeline ISM001-055 shows excellent clinical potential, with the AI pharmaceutical industry expected to reach critical validation points in 2026 [5] Group 6 - Guosheng Securities maintains a "buy" rating for H&H International Holdings, forecasting strong double-digit growth in market share for ANC in mainland China and robust double-digit growth for BNC infant formula [7] - Interest expense optimization is expected to enhance profits, with BNC share gains and accelerated growth in ANC/PNC expected to resonate positively with performance and valuation [7] Group 7 - Guohai Securities maintains a "buy" rating for Geely Automobile, reporting cumulative sales of 476,000 units from January to February 2026, a 1.0% year-on-year increase [8] - New vehicle launches, including Galaxy M7 and Zeekr 8X, are expected to drive growth, with clear strategies for electrification, intelligence, premiumization, and globalization [8] Group 8 - Industrial Securities maintains a "buy" rating for Jiangnan Buyi, reporting a 7.0% year-on-year revenue increase and a 12.5% increase in net profit for FY26H1 [10] - Online revenue grew by 25.1%, with a 16.3% increase in LESS women's wear, and active membership reached 596,000, with high-value members contributing 60% of offline retail sales [10] Group 9 - Shenwan Hongyuan maintains a "buy" rating for Nine Dragons Paper, reporting a 225.1% increase in net profit for FY26H1 and a net profit of 119 yuan per ton [11] - The company produced 2.3 million tons of wood pulp, a 77% year-on-year increase, benefiting from the release of integrated pulp and paper advantages [11]

Group 1: Berteli / Automotive Parts - The company plans to acquire 50.9727% of Yubei Steering, enhancing its steering business capabilities. The acquisition involves purchasing shares from multiple stakeholders, with a valuation not exceeding 2.2 billion yuan [3] - Yubei Steering's main business includes the production and sales of automotive steering systems and components, with projected revenues of 3.03 billion yuan and 3.18 billion yuan for 2024 and 2025, respectively [3] - The company has strong development capabilities in mechanical and electronic brake products, aiming to innovate continuously in vehicle brake systems and provide comprehensive solutions [4] Group 2: Geely Automobile - Geely's total sales in February 2026 reached 206,000 units, showing a slight year-on-year increase of 0.6%, while the cumulative sales for January-February were 476,000 units, up 1.0% year-on-year [6][7] - The company is focusing on high-end product launches, with several new models set to debut in the first half of 2026, including the flagship SUV 8X and the hybrid SUV M7 [7][8] - Geely's export performance is strong, with February exports reaching 61,000 units, a year-on-year increase of 138.3%, and cumulative exports for January-February at 121,000 units, up 129.4% [8] Group 3: Great Wall Motors - Great Wall Motors sold 73,000 vehicles in February 2026, with a cumulative sales increase of 2.6% year-on-year for January-February [10][11] - The company aims to achieve a total sales target of 1.8 million vehicles for 2026, with 600,000 units expected to come from overseas markets [11][12] - The upcoming V9X model, a luxury six-seat SUV, is set to launch in the second quarter of 2026, featuring advanced technology and performance specifications [12] Group 4: Leap Motor - Leap Motor delivered 28,000 vehicles in February 2026, marking an 11.0% year-on-year increase, with a cumulative delivery of 60,000 units for January-February, up 19.2% [14][15] - The company plans to launch several new models in 2026, including the A10, which emphasizes intelligent features and long-range capabilities [15] - Leap Motor is initiating a new retail strategy to enhance customer experience and diversify sales channels [15] Group 5: Swine Breeding Industry - The swine breeding industry is facing intensified losses, with a potential restart of capacity reduction measures. The national breeding sow inventory decreased by 2.9% year-on-year as of December 2025 [17][18] - The industry is seeing increased concentration, with the top 20 swine breeding companies accounting for 36% of the market share, up 5 percentage points year-on-year [17] - The report suggests a left-side layout for the swine breeding sector, recommending leading companies such as Muyuan Foods and Wens Foodstuffs [18] Group 6: BeiGene / Chemical Pharmaceuticals - BeiGene reported a total revenue of $5.34 billion in 2025, a 40% year-on-year increase, with product revenue also growing by 40% [25][26] - The company expects to achieve revenue guidance of $6.2 to $6.4 billion for 2026, with significant contributions from its key products [25] - The rapid growth of its drug Zebrutinib, particularly in the U.S. market, is a key driver of revenue, with a global sales figure of $3.9 billion in 2025 [26][27]

Core Insights - The company reported 2025 revenue of $5.343 billion, a 40% year-over-year increase, with product revenue at $5.282 billion, also up 40% [1] - GAAP net profit reached $287 million, slightly below expectations due to a one-time equity investment impairment and non-recurring tax issues in Q4 2025; excluding these impacts, net profit is expected to meet projections [1] Revenue Growth - Zebutinib drove steady product revenue growth, with 2025 sales of $3.9 billion, a 49% increase year-over-year; quarterly sales were $790 million, $950 million, $1.04 billion, and $1.15 billion, with quarter-over-quarter changes of -4%, +20%, +10%, and +10% respectively [2] - Global sales of Tislelizumab reached $740 million in 2025, a 19% increase year-over-year; GAAP net profit of $287 million marked the first quarterly profit [2] Future Guidance - The company maintains strong growth guidance for 2026, projecting full-year revenue between $6.2 billion and $6.4 billion, a 16-20% increase; GAAP gross margin is expected to remain high at around 80% [2] - GAAP operating expenses are projected to be between $4.7 billion and $4.9 billion, a year-over-year increase of 11-16%; GAAP operating profit is expected to be between $700 million and $800 million [2] Upcoming Catalysts - The company anticipates several key catalysts in 2026, including potential approval for Sotorasib in R/R MCL in 1H26, and accelerated approval for BTK CDAC in R/R CLL based on Phase II data in 2H26 [3] - Phase III trials for CDK4 in 1L breast cancer are set to start in 1H26, with Phase I data expected to be disclosed in the same period; B7-H4 ADC Phase III trials will also commence within 12 months, with Phase I data to be released in 1H26 [3] Profit Forecast and Valuation - Considering domestic healthcare price adjustments and cost control, the company has lowered its 2026 revenue forecast by 2.7% but maintains a profit forecast of $610 million, introducing a 2027 profit forecast of $870 million [4] - The company maintains an outperform rating, with target prices based on DCF model set at 320 CNY, 250 HKD, and 420 USD, representing upside potentials of 36.2%, 40.1%, and 41.4% respectively [4]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company reported a sales figure of $1.1 billion for Zebutinib in Q4, representing a year-over-year increase of 38% and a quarter-over-quarter increase of 10%. Sales in the U.S. reached $845 million, with a year-over-year increase of 37% and a quarter-over-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-over-year to 90.5%, while the general and administrative expense ratio decreased by 7.7 percentage points year-over-year. The non-GAAP net profit surged to $225 million year-over-year [1] - The company guides for revenue between $6.2 billion to $6.4 billion by 2026, with GAAP operating expenses projected at $4.7 billion to $4.9 billion, and a gross margin expected to remain high in the 80% range. The non-GAAP net profit is forecasted to be between $1.4 billion to $1.5 billion [1] Business Focus Areas - The company is focusing on four major areas: 1) Chronic Lymphocytic Leukemia (CLL): Sotoclisib is expected to be launched in Europe and the U.S. within the year, with BTKCDAC anticipated to submit for approval in the second half of 2026. The fixed-cycle therapy of Zebutinib and Sotoclisib has recently initiated a Phase III trial [2] 2) Other Hematological Malignancies: Leveraging Zebutinib, Sotoclisib, and CD19/CD20 targeted tri-antibodies, bispecific antibodies, and cell therapies to expand into other lymphomas, multiple myeloma (MM), and acute myeloid leukemia (AML) indications [2] 3) Solid Tumors: Focused on breast cancer, lung cancer, and gastrointestinal tumors. Recent success in PD-1 and HER2 bispecific antibody combined with chemotherapy in first-line HER2+ gastric cancer is expected to expand overseas application scenarios. CDK4, B7H4ADC, and GPC3/4-1BB bispecific antibodies are either in or will initiate registration studies within the next 12 months [2] 4) Inflammation/Immunology: Early data for BTKCDAC and IRAK4CDAC is expected to be read out in 2026 [2]

Core Viewpoint - The report from CMB International highlights the strong sales performance of BeiGene (06160.HK) in Q4, with a significant year-over-year increase in revenue and profitability, indicating a positive outlook for the company and maintaining a "Buy" rating. Financial Performance - BeiGene's sales of Zebrutinib reached $1.1 billion in Q4, representing a year-over-year increase of 38% and a quarter-over-quarter increase of 10% [1] - Sales in the U.S. amounted to $845 million, with a year-over-year increase of 37% and a quarter-over-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-over-year to 90.5% [1] - General and administrative expenses decreased by 7.7 percentage points year-over-year [1] - Non-GAAP net profit surged to $225 million year-over-year [1] Future Guidance - The company projects revenue between $6.2 billion and $6.4 billion for 2026 [1] - GAAP operating expenses are expected to be between $4.7 billion and $4.9 billion [1] - Gross margin is anticipated to remain high in the 80% range [1] - Non-GAAP net profit is forecasted to be between $1.4 billion and $1.5 billion [1] Market Position and Analyst Ratings - BeiGene's market capitalization is approximately HKD 274.15 billion, ranking first in the biopharmaceutical II industry [1] - The majority of investment banks maintain a "Buy" rating for the stock, with two firms issuing buy ratings in the last 90 days [1] - The average target price over the last 90 days is HKD 223.43 [1] - Guotai Junan Securities recently issued a "Buy" rating for BeiGene [1]

Group 1 - The core viewpoint of the report indicates that BeiGene's (06160) sales of Zebrutinib reached $1.1 billion in Q4 last year, representing a year-on-year increase of 38% and a quarter-on-quarter increase of 10% [1] - The sales in the U.S. amounted to $845 million, with a year-on-year increase of 37% and a quarter-on-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-on-year to 90.5%, while the general and administrative expense ratio decreased by 7.7 percentage points year-on-year [1] Group 2 - The company is focusing on four major areas: 1) Chronic Lymphocytic Leukemia (CLL) with potential launches of Sotigalimab in Europe and the U.S. within the year, and BTK CDAC expected to submit for approval in 2H26 [2] - 2) Other hematological malignancies leveraging Zebrutinib and Sotigalimab along with CD19/CD20 targeted therapies to expand into other lymphomas, multiple myeloma (MM), and acute myeloid leukemia (AML) [2] - 3) Solid tumors with a focus on breast cancer, lung cancer, and gastrointestinal tumors, including recent success in a PD-1 + HER2 dual antibody + chemotherapy regimen for 1L HER2+ gastric cancer [2] - 4) Inflammation/Immunology with early data from BTK CDAC and IRAK4 CDAC expected to be read out in 2026 [2]

Group 1 - The core viewpoint of the report indicates that BeiGene's (06160) sales of Zebrutinib reached $1.1 billion in Q4 last year, representing a year-on-year increase of 38% and a quarter-on-quarter increase of 10% [1] - U.S. sales accounted for $845 million, with a year-on-year increase of 37% and a quarter-on-quarter increase of 14% [1] - The gross margin improved by 4.7 percentage points year-on-year to 90.5%, while the general and administrative expense ratio decreased by 7.7 percentage points [1] Group 2 - The company is focusing on four major areas: 1) Chronic Lymphocytic Leukemia (CLL) with potential launches of Sotigalimab in Europe and the U.S. within the year, and plans to submit a BTK CDAC application in 2H26 [2] - 2) Other hematological malignancies leveraging Zebrutinib and Sotigalimab, along with CD19/CD20 targeted therapies to expand into other lymphomas, multiple myeloma (MM), and acute myeloid leukemia (AML) [2] - 3) Solid tumors with a focus on breast cancer, lung cancer, and gastrointestinal tumors, having recently achieved success with a PD-1 + HER2 dual antibody + chemotherapy regimen in 1L HER2+ gastric cancer [2] - 4) Inflammation/Immunology with early data expected from BTK CDAC and IRAK4 CDAC in 2026 [2] Group 3 - The company has guided for revenues of $6.2 billion to $6.4 billion by 2026, with GAAP operating expenses projected at $4.7 billion to $4.9 billion, and a gross margin expected to remain high in the 80% range [1] - Non-GAAP net profit is anticipated to be between $1.4 billion and $1.5 billion [1] - The company maintains a "Buy" rating [1]

Core Viewpoint - Company maintains a "Buy" rating for BeiGene (06160) due to strong product growth and a promising R&D pipeline, with significant increases in net profit forecasts for 2026, 2027, and 2028 [1] Group 1: Performance Overview - In 2025, the company reported total revenue of $5.3 billion, a year-on-year increase of 40%, and achieved a GAAP net profit of $287 million, marking a return to profitability [1] - In Q4 2025, total revenue reached $1.5 billion, up 33% year-on-year, with a GAAP net profit of $66.5 million, also indicating a return to profitability [1] Group 2: Product Sales Growth - Zebutinib continues to show rapid growth, achieving sales of $1.15 billion in Q4 2025, a year-on-year increase of 39% and a quarter-on-quarter increase of 10%, maintaining its leadership in the global BTKi market [2] - The U.S. market remains the primary revenue source for Zebutinib, generating $840 million in sales, a year-on-year increase of 37% and a quarter-on-quarter increase of 14% [2] - The European market is also growing, with sales of $167 million in Q4 2025, reflecting a year-on-year increase of 47% and a quarter-on-quarter increase of 2% [2] - Additionally, Tislelizumab achieved sales of $18.2 million in Q4 2025, representing an 18% year-on-year increase [2] Group 3: 2026 Full-Year Guidance - The company provided guidance for 2026, projecting total revenue between $6.2 billion and $6.4 billion, with GAAP operating expenses estimated at $4.7 billion to $4.9 billion [3] - The gross margin is expected to remain high, around 80%, with GAAP operating profit forecasted between $700 million and $800 million, and non-GAAP operating profit between $1.4 billion and $1.5 billion [3] Group 4: R&D Pipeline Progress - The company anticipates several key R&D milestones, including mid-term analysis for Zebutinib in MCL in H1 2026 and potential approvals for various drugs in the pipeline [4] - Specific upcoming milestones include the initiation of Phase III clinical trials for multiple drugs and the submission of applications for accelerated approval for others [4] - Data disclosures are expected in H1 2026 for several clinical trials, with additional data releases planned for H2 2026 [4]

Core Viewpoint - Company maintains a "Buy" rating for BeiGene (06160) due to strong product growth and a promising R&D pipeline, with significant increases in net profit forecasts for 2026, 2027, and 2028 [1] Group 1: Performance Overview - In 2025, the company reported total revenue of $5.3 billion, a year-on-year increase of 40%, and achieved a GAAP net profit of $287 million, marking a return to profitability [1] - In Q4 2025, total revenue reached $1.5 billion, up 33% year-on-year, with a GAAP net profit of $66.5 million, also indicating a return to profitability [1] Group 2: Product Sales Growth - Zebutinib continues to show rapid growth, achieving sales of $1.15 billion in Q4 2025, a year-on-year increase of 39% and a quarter-on-quarter increase of 10%, maintaining its leadership in the global BTKi market [2] - The U.S. market remains the primary revenue source for Zebutinib, generating $840 million in sales, a year-on-year increase of 37% and a quarter-on-quarter increase of 14% [2] - The European market is also growing, with sales of $167 million in Q4 2025, reflecting a year-on-year increase of 47% and a quarter-on-quarter increase of 2% [2] - Additionally, Tislelizumab achieved sales of $18.2 million in Q4 2025, a year-on-year increase of 18% [2] Group 3: 2026 Full-Year Guidance - The company provided guidance for 2026, projecting total revenue between $6.2 billion and $6.4 billion, with GAAP operating expenses estimated at $4.7 billion to $4.9 billion [3] - The gross margin is expected to remain high, around 80%, with GAAP operating profit forecasted between $700 million and $800 million, and non-GAAP operating profit between $1.4 billion and $1.5 billion [3] Group 4: R&D Pipeline Progress - The company anticipates several key R&D milestones, including mid-term analysis for Zebutinib in MCL in H1 2026 and potential approvals for various drugs in the pipeline [4] - Specific upcoming events include the initiation of Phase III clinical trials for multiple drugs and the disclosure of early clinical data for several candidates in H1 and H2 2026 [4]